Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

Surviving cancer is often not a patient’s most challenging battle

With advances in treatment and screening for earlier detection, oncologists have improved cancer survival rates dramatically. That is excellent news, but the surging number of survivors means it is increasingly important for providers to focus more diligently on what patients need to thrive after treatment.

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community. The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”

HHS Secretary Robert F. Kennedy Jr. said he is considering a ban on government scientists publishing their work in top-tier medical journals, which he says are abed with pharmaceutical companies.

May 30, 2025

Vol.51 No.21

By Claire Marie Porter

Cancer Policy

MAHA report “Making our Children Healthy Again” focuses on ultraprocessed foods and is mum on tobacco

A recent report from the Make America Healthy Again Commission cites ultraprocessed foods, electromagnetic radiation, and herbicides as possible reasons for increased cancer incidence in children.

KU Cancer Center breaks ground for new complex

The University of Kansas Cancer Center broke ground on the future site of a new complex on May 22 that will bring research and patient care into one area for the first time in KU Cancer Center’s history.

May 30, 2025

Vol.51 No.21

Drugs & Targets

FDA grants priority review for sevabertinib in HER2-mutant NSCLC

FDA accepted a new drug application and granted priority review designation for the investigational compound sevabertinib (BAY 2927088), an oral, small molecule, tyrosine kinase inhibitor, for the treatment of adult patients with advanced non-small cell lung cancer whose tumors have activating human epidermal growth factor receptors 2 (HER2) (ERBB2) mutations and who have received a prior systemic therapy.

May 30, 2025

Vol.51 No.21

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit

Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

YOU MAY BE INTERESTED IN

Surviving cancer is often not a patient’s most challenging battle

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”

MAHA report “Making our Children Healthy Again” focuses on ultraprocessed foods and is mum on tobacco

KU Cancer Center breaks ground for new complex

FDA grants priority review for sevabertinib in HER2-mutant NSCLC

Renew today!

Subscriber content

Never miss an issue!

Login